Several announcements this week made plain that maintaining U.S. leadership in biotechnology is a top administration priority, and that AI is the tool it intends to use to secure it. Across OSTP, HHS, and FDA, the same themes recurred: compressing development timelines, closing gaps in foundational research, and reengineering the federal science funding for the AI age.
“Golden Age” Report on Federal Funding: On July 21, Office of Science and Technology Policy (OSTP) Director Michael Kratsios released Science: A New Golden Age, billed as the first comprehensive rethinking of the U.S. science enterprise since Vannevar Bush’s Science: The Endless Frontier over 80 years ago, paired with an FY2028 R&D Priorities Memorandum issued with OMB Director Russ Vought that directs federal agencies to submit implementation action plans within 90 days and fold the guidance into their FY2028 budgets. AI is the organizing principle throughout with the report calling for reengineering research…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
